Journal article
Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes
Abstract
Aims/hypothesisThe Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) trial reported that 3 years of therapy with rosiglitazone reduced the primary outcome of diabetes or death by 60%. Here we investigated whether an effect on diabetes prevention persists more than 1.5 years after therapy has been discontinued.MethodsThe DREAM On passive follow-up study was conducted at 49 of the 191 DREAM sites. Consenting …
Authors
DREAM On (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Ongoing Follow-up) Investigators
Journal
Diabetologia, Vol. 54, No. 3, pp. 487–495
Publisher
Springer Nature
Publication Date
3 2011
DOI
10.1007/s00125-010-1985-4
ISSN
0012-186X